Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus

Veterinary Microbiology

Volumn 165, Issue 3-4, 2013, Pages 333-340

  Romanutti, Carina ^a   D'Antuono, Alejandra ^a   Palacios, Carlos ^a   Quattrocchi, Valeria ^b   Zamorano, Patricia ^b   La Torre, Jose ^a   Mattion, Nora ^a  

^a Instituto de Ciencia y Tecnología Dr Cesar Milstein CONICET ^*  (Argentina)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

Author keywords

Adenovirus vectors; FMDV; Herpesvirus amplicons; Marker vaccines; Prime boost regimens

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; FOOT AND MOUTH DISEASE VACCINE; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; MARCOL MONTANIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

AMPLICON; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMBRYO; FOOT AND MOUTH DISEASE VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; TH1 CELL; VACCINATION; VIRUS INACTIVATION;

ADENOVIRIDAE; ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; HERPESVIRIDAE; MIRIDAE; MUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC VECTORS; HEK293 CELLS; HERPESVIRIDAE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 84893019687     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2013.04.017     Document Type: Article

References (36)

1. Barnard A.L., Arriens A., Cox S., Barnett P., Kristensen B., Summerfield A., McCullough K.C. Immune response characteristics following emergency vaccination of pigs against foot-and-mouth disease. Vaccine 2005, 23:1037-1047.
2. Berinstein A., Piatti P., Gaggino O.P., Schudel A., Sadir A. Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the Mycobacterium sp. wall. Vaccine 1991, 9:883-888.
3. Borrego B., Fernandez-Pacheco P., Ganges L., Domenech N., Fernandez-Borges N., Sobrino F., Rodriguez F. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses. Vaccine 2006, 24:3889-3899.
4. Borrego B., Argilaguet J.M., Perez-Martin E., Dominguez J., Perez-Filgueira M., Escribano J.M., Sobrino F., Rodriguez F. A DNA vaccine encoding foot-and-mouth disease virus B and T-cell epitopes targeted to class II swine leukocyte antigens protects pigs against viral challenge. Antiviral Res. 2011, 92:359-363.
5. Carrillo C., Wigdorovitz A., Oliveros J.C., Zamorano P.I., Sadir A.M., Gomez N., Salinas J., Escribano J.M., Borca M.V. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. 1998, 72:1688-1690.
6. Collen T., Pullen L., Doel T.R. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model. J. Gen. Virol. 1989, 70:395-403.
7. Cox S.J., Aggarwal N., Statham R.J., Barnett P.V. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 2003, 21:1336-1347.
8. D'Antuono A., Laimbacher A.S., La Torre J., Tribulatti V., Romanutti C., Zamorano P., Quattrocchi V., Schraner E.M., Ackermann M., Fraefel C., Mattion N. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization. Vaccine 2010, 28:7363-7372.
9. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010, 17:261-271.
10. Doel T.R. Optimisation of the immune response to foot-and-mouth disease vaccines. Vaccine 1999, 17:1767-1771.
11. Doel T.R. FMD vaccines. Virus Res. 2003, 91:81-99.
12. Duke C.M., Maguire C.A., Keefer M.C., Federoff H.J., Bowers W.J., Dewhurst S. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 2007, 25:7410-7421.
13. Dus Santos M.J., Wigdorovitz A., Maradei E., Periolo O., Smitsaart M.V., Borca M.V., Sadir A.M. A comparison of methods for measuring the antibody response in mice and cattle following vaccination against foot and mouse disease. Vet. Res. Commun. 2000, 24:261-273.
14. Fernandez F.M., Borca M.V., Sadir A.M., Fondevila N., Mayo J., Schudel A.A. Foot-and-mouth disease virus (FMDV) experimental infection: susceptibility and immune response of adult mice. Vet. Microbiol. 1986, 12:15-24.
15. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33:227-234.
16. Grubman M.J., Lewis S.A., Morgan D.O. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine 1993, 11:825-829.
17. Li Y., Stirling C.M., Denyer M.S., Hamblin P., Hutchings G., Takamatsu H.H., Barnett P.V. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine 2008, 26:2647-2656.
18. Lin S.C., Huang M.H., Tsou P.C., Huang L.M., Chong P., Wu S.C. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE 2011, 6:e20052.
19. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21:346-351.
20. Mattion N., Konig G., Seki C., Smitsaart E., Maradei E., Robiolo B., Duffy S., Leon E., Piccone M., Sadir A., Bottini R., Cosentino B., Falczuk A., Maresca R., Periolo O., Bellinzoni R., Espinoza A., La Torre J., Palma E. Reintroduction of foot-and-mouth disease in Argentina: characterization of the isolates and development of tools for the control and eradication of the disease. Vaccine 2004, 22:4149-4162.
21. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999, 263:496-506.
22. Mulcahy G., Gale C., Robertson P., Iyisan S., DiMarchi R.D., Doel T.R. Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus. Vaccine 1990, 8:249-256.
23. Perciani C.T., Peixoto P.S., Dias W.O., Kubrusly F.S., Tanizaki M.M. Improved method to calculate the antibody avidity index. J. Clin. Lab. Anal. 2007, 21:201-206.
24. Quattrocchi V., Langellotti C., Pappalardo J.S., Olivera V., Di Giacomo S., van Rooijen N., Mongini C., Waldner C., Zamorano P.I. Role of macrophages in early protective immune responses induced by two vaccines against foot and mouth disease. Antiviral Res. 2011, 92:262-270.
25. Reyes-Sandoval A., Rollier C.S., Milicic A., Bauza K., Cottingham M.G., Tang C.K., Dicks M.D., Wang D., Longley R.J., Wyllie D.H., Hill A.V. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol. Ther. 2012, 20:1633-1647.
26. Rodriguez A., Goudsmit J., Companjen A., Mintardjo R., Gillissen G., Tax D., Sijtsma J., Weverling G.J., Holterman L., Lanar D.E., Havenga M.J., Radosevic K. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect. Immun. 2008, 76:1709-1718.
27. Saeki Y., Fraefel C., Ichikawa T., Breakefield X.O., Chiocca E.A. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. 2001, 3:591-601.
28. Sanz-Parra A., Jimenez-Clavero M.A., Garcia-Briones M.M., Blanco E., Sobrino F., Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 1999, 259:129-134.
29. Sanz-Parra A., Vazquez B., Sobrino F., Cox S.J., Ley V., Salt J.S. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J. Gen. Virol. 1999, 80:671-679.
30. Seki C., Robiolo B., Periolo O., Iglesias M., D'Antuono A., Maradei E., Barros V., La Torre J., Mattion N. Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies. Vet. Microbiol. 2009, 133:239-251.
31. Sobrino F., Domingo E. Foot-and-mouth disease in Europe. FMD is economically the most important disease of farm animals. Its re-emergence in Europe is likely to have consequences that go beyond severe alterations of livestock production and trade. EMBO Rep. 2001, 2:459-461.
32. Sun Y., Li N., Li H.Y., Li M., Qiu H.J. Enhanced immunity against classical swine fever in pigs induced by prime-boost immunization using an alphavirus replicon-vectored DNA vaccine and a recombinant adenovirus. Vet. Immunol. Immunopathol. 2010, 137:20-27.
33. Vaine M., Wang S., Hackett A., Arthos J., Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28:2999-3007.
34. Wigdorovitz A., Zamorano P., Fernandez F.M., Lopez O., Prato-Murphy M., Carrillo C., Sadir A.M., Borca M.V. Duration of the foot-and-mouth disease virus antibody response in mice is closely related to the presence of antigen-specific presenting cells. J. Gen. Virol. 1997, 78:1025-1032.
35. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 2004, 25:98-104.
36. Zhang C., Wang B., Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease. Virol. J. 2011, 8:7.